BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 26206590)

  • 21. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
    Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
    J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Barni S
    Clin Lung Cancer; 2012 Mar; 13(2):107-14. PubMed ID: 22056888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.
    Ying M; Zhu X; Chen K; Sha Z; Chen L
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1427-39. PubMed ID: 25577224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.
    Vale CL; Burdett S; Fisher DJ; Navani N; Parmar MK; Copas AJ; Tierney JF
    Clin Lung Cancer; 2015 May; 16(3):173-182.e4. PubMed ID: 25547901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Alimujiang S; Zhang T; Han ZG; Yuan SF; Wang Q; Yu TT; Shan L
    Asian Pac J Cancer Prev; 2013; 14(4):2413-9. PubMed ID: 23725150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Zhang M; Guo H; Zhao S; Wang Y; Yang M; Yu J; Yan Y; Wang Y
    Oncotarget; 2016 Jun; 7(26):39823-39833. PubMed ID: 27223081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
    Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
    PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
    Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
    Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis.
    Xu C; Zhou Q; Wu YL
    J Hematol Oncol; 2012 Oct; 5():62. PubMed ID: 23050865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib for advanced non-small cell lung cancer.
    Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
    Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
    Castellanos EH; Horn L
    Curr Treat Options Oncol; 2015 Oct; 16(10):51. PubMed ID: 26364032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.